BR 1733
Alternative Names: BR-1733Latest Information Update: 09 Mar 2023
At a glance
- Originator Shanghai Blueray Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Mar 2023 BR 1733 is available for licensing as of 09 Mar 2023 (Shanghai Blueray Biopharma website, March 2023)
- 01 Mar 2023 Shanghai Blueray Biopharma plans a phase-I/II trial for Cancer (Late-stage disease; Second-line or greater) in April 2023 (PO) (NCT05749549)
- 01 Mar 2023 Preclinical trials in Cancer in China before March 2023 (PO)